x

SYMPOSIUM: Humanized Drug Target and Organoid Platforms for Oncology New Drug Development

19th February 2021 13:30 – 17:10 – Taipei International Convention Center (TICC), Room 102

SYMPOSIUM: Humanized Drug Target and Organoids Platform on Oncology New Drug DevelopmentCrown Bioscience invites you to attend a symposium focusing on in vivo and in vitro solutions for immunotherapy assessment. We have assembled a panel of thought leaders who will present their most innovative data alongside CrownBio´s Scientists who will discuss our I/O platforms, including humanized target knock-in models and in vitro organoid co-cultures and how to apply them to drug development and translational research.

Attend this Symposium to Explore:

  • How on-target toxicities caused by systemic administration of antibody drugs can limit their application

  • The potential of HUB Organoid Technology in vitro and how tumor organoids can be established, maintained, and applied to precision oncology

  • The benefits of patient-relevant 3D in vitro platforms in oncology drug development

Presentations and Speakers

Pan-Chyr Yang

Professor, Taiwan University
Opening Remarks

Kevin Wang

Vice President, Crown Bioscience Inc.
CrownBio New Drug Research and Development Platform

Tian-Lu Cheng

Professor, Kaohsiung Medical University
An autologous hinge as a universal antibody lock enhances antibody selectivity and safety

Ying Chih Chang

Researcher, Academia Sinica
Single Cell Derived Organoids toward Precision Medicine

Kevin Buyens

Head of Corporate Development & Strategy, Crown Bioscience Inc.
Organoid Briefing

Dr. Xiaoxi Xu

Head of Organoid Platform, Crown Bioscience Inc.
Applications of Patient-Derived Cancer Organoids in Drug Development and Translational Research

Dr. Hongjuan Zhang

Senior Scientist of Cancer Biology and Immunology, Crown Bioscience Inc.
In vitro Immuno-Oncology and Organoid Co-culture Platforms

Schedule of Events

Time Event
13:30 報到 Registration
14:00 開場致詞
Opening Remarks
生策會副會長 楊泮池院士 & 中美冠科生物技術有限公司 副總裁王簾讀
Institute for Biotechnology and Medicine Industry(IBMI) Vice President Pan-Chyr Yang, Academician of Academia Sinica, Crown Bioscience Inc. Vice President Kevin Wang
14:10 中美冠科新藥研發平台介紹
CrownBio New Drug Research and Development Platform Introduction
中美冠科生物技術有限公司 副總裁王簾讀
Crown Bioscience Inc. Vice President Kevin Wang
14:30 以抗體自體絞鍊區當萬能抗體鎖以增加抗體藥物選擇性與安全性
An Autologous Hinge as a Universal Antibody Lock Enhances Antibody Selectivity and Safety
高雄醫學大學 鄭添祿教授
Kaohsiung Medical University Professor Tian-Lu Cheng
15:00 腫瘤類器官簡介
Organoid Briefing
中美冠科生物技術有限公司 企業發展和戰略主管Kevin Buyens
Crown Bioscience Inc. Head of Corporate Development & Strategy Kevin Buyens
15:10 茶敘 Coffee Break & Network
15:40 單細胞衍生類器官細胞平台及精準醫學的應用
Single Cell Derived Organoids Toward Precision Medicine
中央研究院 張瑛芝研究員
Academia Sinica Researcher Ying Chih Chang
16:10 人源腫瘤類器官在藥物研發和轉化醫學中的應用
Applications of Patient-Derived Cancer Organoids in Drug Development and Translational Research 中美冠科生物技術有限公司 類器官平臺負責人徐小溪博士
Crown Bioscience Inc. Head of Organoid Platform Dr. Xiaoxi Xu
16:40 腫瘤類器官在體外免疫共培養中的應用
In vitro Immuno-Oncology and Organoid Co-culture Platforms
中美冠科生物技術有限公司 腫瘤生物學與免疫學高級科學家张红娟博士
Crown Bioscience Inc. Senior Scientist of Cancer Biology and Immunology Dr. Hongjuan Zhang

Register now to reserve your seat!

Reserve Your Seat

Your privacy is important to us.
We'll never share your information.

SHARE THIS